Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study

Table 3 Changes in clinical parameters from baseline to 12 months in both groups

	Δ, m-TOR group ( P)	Δ, Control group ( P)	Δ, Effect (m-TOR vs.Control), (95% CI)	P value
BMI (kg/m ² )	1.37 ± 7	0.2 ± 5	1.1 ± 1.3	0.459
BMI (kg/m ² )	(0.2)	(0.7)	(-1.8 to 4)	0.459
Systolic blood pressure (mmHg)	-1.7 ± 12	0.98 ± 12	2.6 ± 2.7	0.324
Systolic blood pressure (mmHg)	(0.6)	(0.4)	(-8 to 2.7)	0.324
Diastolic blood pressure (mmHg)	-2.8 ± 16	0.7 ± 14.7	-3.6 ± 3.5	0.326
Diastolic blood pressure (mmHg)	(0.7)	(0.3)	(-10 to 3.6)	0.326
Serum creatinine (mg/dL)	-0.44 ± 22	-0.55 ± 24	0.1 ± 5.4	0.985
Serum creatinine (mg/dL)	(0.7)	(0.4)	(-10.8 to 11)	0.985
Hemoglobin (g/dL)	-7.6 ± 6.6	-6 ± 16	-1.7 ± 2.6	0.503
Hemoglobin (g/dL)	(0.0001)	(0.002)	(-6.8 to 3.4)	0.503
Uprot (mg/24 h)	-278 ± 572	-6.1 ± 98	-271.6 ± 116	0.028
Uprot (mg/24 h)	(0.003)	(0.4)	(-511 to -32)	0.028
Cholesterol (mg/dL)	-12.1 ± 22	-5.9 ± 21	-6.2 ± 5.2	0.243
Cholesterol (mg/dL)	(0.01)	(0.15)	(-17 to 4.3)	0.243
Triglycerides (mg/dL)	-24.6 ± 58	6.3 ± 33	-31 ± 12.3	0.017
Triglycerides (mg/dL)	(0.08)	(0.010)	(-56 to -5.8)	0.017

Δ, percent increase or decrease from baseline ([baseline value – final value] x 100/baseline value). Data are expressed as mean ± SD. Values in parentheses are P values for the differences between final and baseline absolute values, and 95% confidence intervals for the control versus m-TOR group effect.
To convert serum creatinine in mg/dL to mol/L, multiply by 88.4; hemoglobin in g/dL to g/L, multiply by 10; cholesterol in mg/dL to mmol/L, multiply by 0.02586; triglycerides in mg/dL to mmol/L, multiply by 0.01129.
Abbreviations: BMI, body mass index; Uprot, daily urinary protein excretion.

ISSN: 1471-2369